Benitec Biopharma (BNTC)
(Delayed Data from NSDQ)
$8.15 USD
-0.01 (-0.12%)
Updated Sep 13, 2024 03:59 PM ET
After-Market: $8.13 -0.02 (-0.25%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Benitec Biopharma Limited (BNTC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$19.00 | $30.00 | $13.00 | 132.84% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Benitec Biopharma Limited comes to $19.00. The forecasts range from a low of $13.00 to a high of $30.00. The average price target represents an increase of 132.84% from the last closing price of $8.16.
Analyst Price Targets (4 )
Broker Rating
Benitec Biopharma Limited currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on three recommendations.
Of the four recommendations deriving the current ABR, four are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 3 | 3 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/12/2024 | Guggenheim Securities | Debjit Chattopadhyay | Not Available | Strong Buy |
7/22/2024 | SVB Securities | Mani Foroohar | Not Available | Strong Buy |
6/13/2024 | Piper Sandler | Yasmeen Rahimi | Not Available | Strong Buy |
4/22/2024 | JMP Securities | Silvan C Tuerkcan | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 4 |
Average Target Price | $19.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 253 |
Current Quarter EPS Est: | -0.58 |
BNTC FAQs
Benitec Biopharma Limited (BNTC) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 4 brokerage firms.
The average price target for Benitec Biopharma Limited (BNTC) is $19.00. The current on short-term price targets is based on 2 reports.
The forecasts for Benitec Biopharma Limited (BNTC) range from a low of $13 to a high of $30. The average price target represents a increase of $133.13 from the last closing price of $8.15.
The current UPSIDE for Benitec Biopharma Limited (BNTC) is 133.13%
Based on short-term price targets offered by four analysts, the average price target for Benitec Biopharma Limited comes to $19.00. The forecasts range from a low of $13.00 to a high of $30.00. The average price target represents an increase of 132.84% from the last closing price of $8.16.